PineTree Therapeutics is a pre-clinical stage Biotech company that has developed the TAER-TAB™ and ViTRAP™ technologies. These technologies utilize Tumor-Associated essential receptor targeting antibody and virus targeting recombinant agent platforms for infectious diseases technology. The TAER-TAB™ platform is a transformative antibody-based receptor degradation platform that targets and potentially degrades drug-resistant or difficult-to-treat receptors present on many types of tumors and on different types of immune and disease cells. It has the potential to generate many multivalent antibodies to degrade extracellular oncogenic receptors of interest as well as immuno-oncology antibodies to enhance adoptive anti-tumor immunity and prevent tumor recurrence. PineTree Therapeutics is building a broad pipeline for hard-to-treat cancers and viral diseases, with an initial focus on oncology.